סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

elanco animal health gmbh alfred -

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

t.j. smith & nephew limited - klostridio-peptidaza; proteaze, druge - mazilo - klostridio-peptidaza 1,2 i.e. / 1 g  proteaze, druge0,24 i.e. / 1 g; proteaze, druge 0,24 i.e. / 1 g - kolagenaza

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hipertenzija - antagonisti angiotenzina ii, navadni - hypertensiontreatment bistvenih hipertenzije pri odraslih. kardiovaskularni preventionreduction za srčno-žilne obolevnosti pri bolnikih z:manifest atherothrombotic bolezni srca in ožilja (zgodovina bolezni srca in ožilja, kap, ali periferne arterijske bolezni) ali tipa 2 sladkorna bolezen z dokumentiranimi ciljni organ škode.

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan, hydrochlorothiazide - hipertenzija - sredstva, ki delujejo na sistem renin-angiotenzin - zdravljenje esencialne hipertenzije. micardisplus določen odmerek kombinacije (40 mg telmisartan / 12. 5 mg hydrochlorothiazide, 80 mg telmisartan / 12. 5 mg hydrochlorothiazide) je indicirano pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na telmisartan sam. micardisplus določen odmerek kombinacije (80 mg telmisartan / 25 mg hydrochlorothiazide) je indicirano pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na micardisplus (80 mg telmisartan / 12. 5 mg hydrochlorothiazide) ali pri bolnikih, ki so bili predhodno stabiliziranih na telmisartan in hydrochlorothiazide podana ločeno.

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan, amlodipine - hipertenzija - sredstva, ki delujejo na sistem renin-angiotenzin - zdravljenje esencialne hipertenzije pri odraslih:add-on therapytwynsta je navedeno pri odraslih, katerih krvni tlak ni ustrezno nadzorovan na amlodipine. zamenjava therapyadult bolnikov, ki prejemajo telmisartan in amlodipine iz ločenih tablet lahko namesto prejeli tablet twynsta, ki vsebuje enake komponente odmerki.

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bayer animal health gmbh 51368 leverkusen nemčija proizvajalec -

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

guidehouse germany gmbh - sotagliflozin - sladkorna bolezen tip 1 - zdravila, ki se uporabljajo pri diabetesu - zynquista je indicirano kot dodatek k insulina terapija za izboljšanje glycaemic nadzor pri odraslih s tipom 1 sladkorne bolezni z indeksom telesne mase (bmi) ≥ 27 kg/m2, ki niso uspeli doseči primerno glycaemic nadzor kljub optimalno insulina terapija.

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicinijev klorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharma resources dr. schluttig gmbh - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel